par Aap Implantate AG (isin : DE0005066609)
Proposed capital measures in connection with the convening of the Annual General Meeting: Maintaining freedom of action in a macroeconomic environment characterized by high uncertainties
EQS-News: aap Implantate AG / Key word(s): AGM/EGM/Corporate Action
Proposed capital measures in connection with the convening of the Annual General Meeting: Maintaining freedom of action in a macroeconomic environment characterized by high uncertainties
14.06.2023 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
The Management Board and Supervisory Board of aap Implantate AG ("aap" or the "Company") have, in the run-up to the adoption of the notice convening the Annual General Meeting to be held on July 25, 2023, intensively considered the Company's situation, its future development and the current and assumed macroeconomic environment in the further course of 2023. Based on the existing high macroeconomic uncertainties in connection with the war in Ukraine, the inflation-related interest rate and cost increases (e.g. development of energy prices and prices for raw materials), but also the current share price of the Company close to the EUR 1 line with a very low daily trading volume, the Executive Board and the Supervisory Board have decided to propose to the Annual General Meeting, among other things, the reduction of the share capital of the Company from currently EUR 8,955,849.00 by EUR 6,716,887.00 to EUR 2,238,962.00 for resolution. This is particularly intended to safeguard the Company's freedom of action for any financing measures.
-------------------------------------------------------
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German Stock Exchanges -
About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, manufactures and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ®, the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while at international level it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. This involves sales both via distribution agents and as part of partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at https://www.aap.de/.
The figures presented in this press release may be subject to technical rounding differences which do not affect the overall presentation.
Forward-looking statements
This release may contain forward-looking statements based on current expectations, beliefs and projections of the Management Board and currently available information. The forward-looking statements are not guarantees of future performance or results. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. We assume no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.
Contact:
aap Implantate AG; Marek Hahn; Member of the Management Board, CFO; Lorenzweg 5; 12099 Berlin
Tel.: Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; E-Mail: m.hahn@aap.de
14.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | aap Implantate AG |
| Lorenzweg 5 | |
| 12099 Berlin | |
| Germany | |
| Phone: | +49 (0) 30 75 01 90 |
| Fax: | +49 (0) 30 75 01 91 11 |
| E-mail: | info@aap.de |
| Internet: | www.aap.de |
| ISIN: | DE000A3H2101 |
| WKN: | A3H210 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1656379 |
| End of News | EQS News Service |
1656379 14.06.2023 CET/CEST